AlloVir Inc (ALVR) Cotización

Then everything went dark as the cash dwindles.

>>Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified

Company to prioritize capital preservation and review strategic options

AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023

ALVR under $2

ALVR 1O Q 2/26

AlloVir shedding 95% of its staff after discontinuing T cell therapy trial
https://www.morningstar.com/news/marketwatch/202401041038/allovir-shedding-95-of-its-staff-after-discontinuing-t-cell-therapy-trial

26s

ALVR new 52 week low

Waiting to see if .20s come

Gilead owns about 13 Million shares of the total 114 Million outstanding.

I think if they offered $1.50 they could buy the rest of the shares for basically the cash on hand less liabilities.

Is the value of the pipeline $0?

I doubt it, but worse case it is.

I don't know, but $0.75-0.80 seems decent even for a bounce just to $1

I am more saying why I would get in should there start to be buy in and support from bigger pockets.

Agree. Not too bright addition.

ALVR new 52 week low

Tpet

Exhibit 99.1 Press release: https://www.sec.gov/Archives/edgar/data/1754068/000119312523301777/d671953dex991.htm

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified
Company to prioritize capital preservation and review strategic options

AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023
Waltham, Mass – December 22, 2023 – AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV). The company will discontinue its three global Phase 3 posoleucel studies – for prevention of clinically significant infections or diseases by multiple viruses, treatment of virus-associated hemorrhagic cystitis (vHC), and treatment of adenovirus (AdV) – following allogeneic hematopoietic cell transplant (allo-HCT). The company made the determination following three pre-planned analyses by three independent Data Safety Monitoring Boards (DSMBs) each of which recommended stopping its respective trial for futility after a review of the data suggested that each study was unlikely to meet its primary endpoint. There were no observed safety concerns raised by any of the DSMBs.

AlloVir is in the process of notifying regulatory agencies and clinical trial investigators involved in these trials of the findings.
“While we are disappointed by the unexpected outcome of these trials, we are encouraged by the apparent safety profile of posoleucel,” said Diana Brainard, MD, Chief Executive Officer of AlloVir. “In light of the DSMB recommendations, we will discontinue the prevention, vHC and AdV Phase 3 trials. We will continue to analyze the data from these studies to understand any variables that may have impacted outcomes or any apparent subpopulation benefits. We thank the patients, investigators and staff who participated in the trials.”

Dr. Brainard continued, “We established pre-planned futility analyses across these three Phase 3 trials, as each assessed a potentially highly innovative treatment for patients suffering with severe and complex medical conditions lacking significant prior clinical development, and we also expected the trials would require substantial additional capital to bring them to completion. With these current results, we will immediately shift our focus to preserve our substantial remaining capital, review our pipeline, and assess strategic options.”

AlloVir will review strategic alternatives for the Company and its portfolio of virus-specific T cell therapies. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction. As of September 30, 2023, AlloVir had cash, cash equivalents and short-term investments of $213.3 million.

About AlloVir’s Earlier Stage Virus-Specific T cell Pipeline

Adult Kidney Transplantation

AlloVir has earlier reported the results of its completed Phase 2 randomized, placebo-controlled trial evaluating posoleucel for the treatment of BKV infection in adult kidney transplant patients. After 24 weeks of treatment, 39% of patients receiving posoleucel experienced a =1-log viral load reduction, compared to 14% of patients receiving placebo.

Acute Respiratory Infection

The company has completed Part A of a randomized, placebo-controlled Phase 1b/2a trial with ALVR106 in 14 stem cell or solid organ transplant patients. ALVR106 is an investigational allogeneic, off-the-shelf, multi-virus-specific VST therapy candidate designed to target diseases caused by human metapneumovirus (hMPV), influenza, parainfluenza virus (PIV) and respiratory syncytial virus (RSV). Data has been accepted for presentation at a scientific conference in the first quarter of 2024.
Chronic Hepatitis B Infection

ALVR107 is an investigational allogeneic, off-the-shelf VST therapy designed to target hepatitis B virus (HBV)-infected cells and potentially cure patients with chronic HBV infection. Preclinical and IND-enabling studies support the advancement of ALVR107 into a clinical proof of concept study as a next step.

About AlloVir

AlloVir is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. For more information, visit www.allovir.com or follow us on X or LinkedIn.

8-K filing:https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312523301777/d671953d8k.htm

Item 7.01
Regulation FD Disclosure
On December 22, 2023, AlloVir, Inc. (“AlloVir”) issued a press release titled “AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T-Cell Therapy.” The press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01
Other Events.
On December 22, 2023, AlloVir announced that it is discontinuing enrollment in its three ongoing Phase 3 Posoleucel studies for (i) prevention of clinically significant infections or diseases by multiple viruses, (ii) treatment of virus-associated hemorrhagic cystitis, and (iii) treatment of adenovirus, all following allogeneic hematopoietic cell transplant.

Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits

Exhibit No. Description
99.1 Press release dated December 22, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

They did say: "we are encouraged by the apparent safety profile of posoleucel".
Yes, water also has a great safety profile, but doesn't cure a damn thing except thirst.
NOT GOOD - NOT GOOD AT ALL.

NOT GOOD NEWS.

The chart never lies

Damn, That was quick

I'm going to wait till next week

Wow I love the technicals analysis....I didn't read the PR or anything I just knew the chart was fugly ugly lol... Fundamentals don't mean squat ....I need to check to see if this is oversold look up the Fibonacci retracement and the stochastic rsi...

Below $1 now.

Report said they have $213.3 million as of Sept 30

With 114 million shares outstanding, this seems cheap?

If this catches a bid, might see a bit of a pop.

Need this below 1.00 then I buy for a flip

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
November 16 2023 - 07:00AM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.


View source version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/

I'm out come below 1s

No below 1s but my 1.30s look good

Tank below 1s

Her come 1.20s

The chart is still in free fall looking for a bottom

No way. Will be a 25-30 Million market cap soon.

Will 1.20s hold

Yes tank more

Come on below 1s please

Need more read below 1s would be a possible buy

Need more

Need more tankage

Tank baby tank below 1s

More red this week nearing a bottom easy flip once stochastic hit 0.... below 1.00 would be excellent

Almost ready

Tank hard then I buy for a flip

Bought more today @ $2.16

Bought more today again under $3

still on watch

Bought more today under $3.

I bought in at under $3. On 6-29 10% owner Gilead Sciences Inc acquired a total 2,930,870 shares an average price of $3.75.

Just started a position in ALVR.

Nobody? What about PL is he here?